Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wellnex Life Ltd ( (AU:WNX) ) has shared an announcement.
Wellnex Life Limited reported a 40.4% increase in total revenue for FY25, reaching $23.6 million, primarily driven by its brands, including Pain Away. Despite a total loss of $15.6 million due to non-cash and one-off expenses, the company’s normalised EBITDA loss improved by 57% to $2.2 million. The dual listing on the AIM market of the London Stock Exchange strengthened Wellnex Life’s balance sheet, settling deferred considerations and convertible notes. The company plans to continue expanding its licensing opportunities and expects strong revenue growth in FY26, aiming to enhance shareholder value and operational profitability.
More about Wellnex Life Ltd
Wellnex Life Limited is a consumer healthcare business that develops, licenses, and markets registered products and brands in the healthcare market segment. Since its listing on the ASX in 2021, the company has launched various brands and products available in major retailers, pharmacies, and supermarkets. Wellnex Life has secured significant licensing arrangements with major pharmaceutical companies globally, enhancing its distribution channels. The acquisition of the Australian topical pain relief brand Pain Away has accelerated the company’s growth and reinforced its position in the healthcare market.
See more data about WNX stock on TipRanks’ Stock Analysis page.